Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00007956
First received: January 6, 2001
Last updated: February 6, 2009
Last verified: February 2002

January 6, 2001
February 6, 2009
November 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00007956 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma
A Phase I Study Of Therapy With Mono-dgA-RFB4 In Patients With Relapsed And Refractory CD22+ B-Cell Lymphoma

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have recurrent or refractory lymphoma.

OBJECTIVES:

  • Determine the maximum tolerated dose and dose-limiting toxicity of monoclonal antibody mono-dgA-RFB4 in patients with recurrent or refractory B-cell lymphoma expressing CD22 antigen.
  • Determine the pharmacokinetic profile of this drug in these patients.
  • Correlate the pharmacokinetic parameters with the biologic effects and/or toxicity of this drug in these patients.
  • Determine whether clinical responses in these patients occur at lower, equal, or higher doses than historical responses induced by a similar drug.

OUTLINE: This is a dose-escalation study. Patients are stratified according to number of circulating tumor cells in peripheral blood (more than 50/mm3 vs 50/mm3 or less).

Patients receive monoclonal antibody Mono-dgA-RFB4 IV over 4 hours on days 1, 3, and 5. Patients achieving complete, partial, or minimal remission receive additional courses of therapy every 4 weeks in the absence of unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of monoclonal antibody mono-dgA-RFB4 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients achieving complete remission or stable partial remission are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 20-25 patients will be accrued for this study within 12-18 months.

Interventional
Phase 1
Primary Purpose: Treatment
Lymphoma
Biological: monoclonal antibody mono-dgA-RFB4
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically confirmed recurrent or refractory B-cell lymphoma after at least 1 standard chemotherapy regimen

    • Low, intermediate, or high grade
    • CD22 antigen on at least 30% of tumor cells by flow cytometry
  • No lymphoblastic lymphoma, B-cell chronic lymphocytic leukemia, B-cell or pre-B-cell acute lymphocytic leukemia, or hairy cell leukemia
  • Measurable disease

    • Positive bone marrow not considered measurable
    • Circulating tumor cells in peripheral blood considered measurable
  • No CNS disease (leptomeningeal or parenchymal)
  • No lymphomatous or infectious pulmonary parenchymal disease
  • No baseline/pleural effusion
  • Ineligible for or refused autologous or allogeneic bone marrow transplantation NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

Age:

  • Over 18

Performance status:

  • ECOG 0-2

Life expectancy:

  • At least 3 months

Hematopoietic:

  • Platelet count greater than 50,000/mm^3
  • Absolute granulocyte count greater than 750/mm^3

Hepatic:

  • Bilirubin less than 1.5 mg/dL
  • SGPT less than 2 times upper limit of normal
  • Albumin greater than 75% lower limit of normal

Renal:

  • Creatinine no greater than 1.4 mg/dL OR
  • Creatinine clearance at least 60 mL/min

Cardiovascular:

  • Ejection fraction greater than 40% by MUGA or echocardiogram

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • No human anti-mouse antibody (HAMA) levels greater than 1 microgram/mL
  • No condition that may require stenting of ureters, stabilization of impending pathological fractures, or relief of airway, bowel, or biliary tract obstruction
  • No other concurrent illness that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • See Disease Characteristics

Chemotherapy:

  • See Disease Characteristics
  • At least 2 weeks since prior chemotherapy and recovered
  • No concurrent chemotherapy

Endocrine therapy:

  • No concurrent corticosteroids unless receiving stable maintenance dose prior to therapy

Radiotherapy:

  • No prior radiotherapy
  • No concurrent radiotherapy

Surgery:

  • Not specified

Other:

  • No other concurrent investigational agents
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00007956
CDR0000068356, NCI-01-C-0021, UTSMC-99-02-07
Not Provided
Not Provided
National Cancer Institute (NCI)
Not Provided
Study Chair: Edward A. Sausville, MD, PhD National Cancer Institute (NCI)
National Cancer Institute (NCI)
February 2002

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP